SCHEMBL2229460

SCHEMBL2229460

CN(C)S(=O)(=O)c1ccccc1Cl

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PGR P06401 1/20 0.54
ALDH1A1 P00352 4/20 0.53
HTT P42858 1/20 0.53
KDM4E B2RXH2 3/20 0.53
HTR2A P28223 1/20 0.53
HTR2C P28335 1/20 0.53
CYP1A2 P05177 1/20 0.53
CYP3A4 P08684 1/20 0.53
CYP2D6 P10635 1/20 0.53
CYP2C9 P11712 1/20 0.53
CYP2C19 P33261 1/20 0.53
MCOLN3 Q8TDD5 1/20 0.51
SMN1; SMN2 Q16637 2/20 0.50
GSTO1 P78417 3/20 0.49
POLB P06746 1/20 0.49
MEN1 O00255 1/20 0.47
KMT2A Q03164 1/20 0.47
HSD11B1 P28845 3/20 0.46
KCNJ6 P48051 1/20 0.44
KCNJ5 P48544 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2642338 0.83 MCOLN3 (0.67) PGRALDH1A1HTTMCOLN3SMN1; SMN2
SCHEMBL10616099 0.80 PGR (0.49) PGRKDM4EHTR2AHTR2CCYP1A2
SCHEMBL6535002 0.80 MCOLN3 (0.78) PGRALDH1A1KDM4EHTR2AHTR2C
SCHEMBL17442030 0.80 CYP1A2 (0.48) ALDH1A1HTTKDM4ECYP1A2CYP3A4
SCHEMBL12077718 0.80 PGR (0.49) PGRALDH1A1HTTKDM4EHTR2A
SCHEMBL10753265 0.79 PGR (0.48) PGRHTTKDM4EHTR2AHTR2C
SCHEMBL7234031 0.78 ALDH1A1 (0.53) ALDH1A1HTTMCOLN3SMN1; SMN2GSTO1
SCHEMBL29978694 0.78 ALDH1A1 (0.53) ALDH1A1HTTMCOLN3SMN1; SMN2GSTO1
SCHEMBL9307687 0.78 SMN1; SMN2 (0.55) PGRALDH1A1HTTHTR2AHTR2C
SCHEMBL12077622 0.77 PGR (0.47) PGRALDH1A1HTTKDM4EHTR2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117535689-A Method for synthesizing sulfonamide through decarbonylation of N, N-dimethylformamide and denitrification of sulfonyl hydrazide under electrochemical condition 湘潭大学 2024-02-09 CN disclosed
EP-2523559-A1 COMPOUNDS AND METHODS GlaxoSmithKline LLC (US) 2012-11-21 EP disclosed
WO-2011088027-A1 COMPOUNDS AND METHODS GLAXOSMITHKLINE LLC (US) 2011-07-21 WO disclosed
CN-101945839-A Process for producing conjugated aromatic compound SUMITOMO CHEMICAL CO 2011-01-12 CN disclosed
US-20100292481-A1 METHOD FOR PRODUCING CONJUGATED AROMATIC COMPOUND SUMITOMO CHEMICAL COMPANY, LIMITED 2010-11-18 US disclosed
EP-2233459-A1 METHOD FOR PRODUCING CONJUGATED AROMATIC COMPOUND Sumitomo Chemical Company, Limited (JP) 2010-09-29 EP disclosed
US-4645527-A PLANT SAFENING AGENT E. I. DU PONT DE NEMOURS AND COMPANY (US) 1987-02-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100292481-A1 METHOD FOR PRODUCING CONJUGATED AROMATIC COMPOUND TYR, PAH, AHR PGR 1515/4885ALDH1A1 816/4885HTT 1087/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.